DrugPatentWatch Database Preview
Details for Patent: 6,762,180
Which drugs does patent 6,762,180 protect, and when does it expire?
Patent 6,762,180 protects OFEV and is included in one NDA.
This patent has sixty patent family members in forty-two countries.
Summary for Patent: 6,762,180
| Title: | Substituted indolines which inhibit receptor tyrosine kinases |
| Abstract: | Indolinones of the formula ##STR1## having an inhibitory effect on receptor tyrosine kinases and cyclin/CDK complexes, as well as on the proliferation of endothelial cells and various tumor cells. Exemplary are: (a) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycar bonyl-2-indolinone, (b) 3-Z-[(1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoy l-2-indolinone, and (c) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-metboxyca rbonyl-2-indolinone. |
| Inventor(s): | Roth; Gerald Juergen (Biberach, DE), Heckel; Armin (Biberach, DE), Walter; Rainer (Biberach, DE), Van Meel; Jacobus (Moedling, AT), Redemann; Norbert (Biberach, DE), Tontsch-Grunt; Ulrike (Baden, AT), Spevak; Walter (Oberrohrbach, AT), Hilberg; Frank (Vienna, AT) |
| Assignee: | Boehringer Ingelheim Pharma KG (Ingelheim, DE) |
| Application Number: | 09/678,682 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; |
Drugs Protected by US Patent 6,762,180
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | OFEV | nintedanib esylate | CAPSULE;ORAL | 205832-001 | Oct 15, 2014 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | |||
| Boehringer Ingelheim | OFEV | nintedanib esylate | CAPSULE;ORAL | 205832-002 | Oct 15, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 6,762,180
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Germany | 199 49 208 | Oct 13, 1999 |
| Germany | 100 42 696 | Aug 31, 2000 |
International Family Members for US Patent 6,762,180
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 026036 | Start Trial | |||
| Austria | 439342 | Start Trial | |||
| Australia | 1023301 | Start Trial | |||
| Australia | 781939 | Start Trial | |||
| Bulgaria | 106587 | Start Trial | |||
| Bulgaria | 65983 | Start Trial | |||
| Brazil | 0014735 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
